Cancer Research

Table of Contents

AACR American Association for Cancer Research

September 1, 2017 • Volume 77 • Number 17

BREAKING ADVANCES

OBITUARY

SPECIAL REPORT

REVIEW

PRIORITY REPORT

MOLECULAR AND CELLULAR PATHOBIOLOGY

TUMOR AND STEM CELL BIOLOGY

Table of Contents

Table of Contents

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

Adenosine is an immunosuppressive metabolite that prevents antitumor immunity and promotes metastatic dissemination. In BRAF-mutant melanoma, adenosine signaling by the A2A adenosine receptor impedes the activity of clinically approved BRAF/MEK-targeted therapies. Using preclinical melanoma models, it was found that targeting adenosine signaling in combination with BRAF/MEK inhibition provided improved tumor control and antimetastatic activity. In addition, combination BRAF/MEK treatment in melanoma patients regulates the expression of CD73, the enzyme that generates adenosine. For details, see article by Young and colleagues on page 4684.



AACR American Association for Cancer Research

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

77 (17)

Cancer Res 2017;77:4543-4737.